Developer docs
API playgroundTry for free, no card

Search company profiles

Cyagen Biosciences

Full company profile

uuid0002or6

Namestring
Cyagen Biosciences
Legal namestring
Cyagen Biomodels LLC
Websiteurl
cyagen.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Cyagen Biosciences is a privately held, AI-enabled preclinical contract research organization founded in 2006 and headquartered in Santa Clara, California, with principal research and operational facilities in Taicang, Jiangsu, China. The company specializes in the design, generation, and commercialization of genetically engineered rodent models (primarily knockout, knockin, transgenic, and humanized mice and rats), custom cell line services, virus packaging, and integrated preclinical efficacy studies across oncology, neuroscience, metabolic and cardiovascular disease, ophthalmology, and autoimmune and inflammatory disease. Its proprietary platform portfolio centers on the HUGO™ family of humanized mouse systems—HUGO-GT™ for gene therapy and oligonucleotide target validation, and the HUGO-Ab™ sub-family (HUGO-Mab™, HUGO-Light™, HUGO-Nano™, HUGO-Ab-eKO™) for fully human antibody and bispecific discovery—combined with the Turboknockout™ gene targeting technology, Cre-ESCs editing, and the Cell iGeneEditor™ / AlphaKnockout systems. More than 50,000 mouse and rat models have been delivered globally, with 16,500+ peer-reviewed SCI citations referencing Cyagen models and services, 250,000 SPF animals housed in AAALAC-accredited facilities, and a workforce exceeding 1,000 employees across 40,000+ square meters of operational footprint.

Short descriptiontext

Cyagen Biosciences is a private AI-enabled preclinical CRO that designs genetically engineered rodent models, humanized mouse platforms, and antibody discovery services for biopharmaceutical companies, academic researchers, and antibody therapeutics developers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSanta Clara, United States
HQ citystring
Santa Clara
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetically engineered models, preclinical CRO services, humanized mouse models, antibody discovery services, virus packaging services
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Preclinical CRO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Custom Genetically Engineered Animal Models
TypeOne Time License
Description

Generation of knockout, knockin, transgenic, and humanized mouse and rat models for preclinical research. Revenue generated through one-time model generation projects and repeat breeding services.

cyagen.com
2Preclinical CRO Services
TypeProfessional Services
Description

Comprehensive preclinical efficacy studies including neuroscience, oncology, ophthalmology, metabolic diseases, autoimmunity, and inflammation research services. Services include breeding, cryopreservation, phenotyping, and custom study execution.

cyagen.com
3Virus Packaging Services
TypeProfessional Services
Description

AAV, lentivirus, and adenovirus packaging for gene therapy, vaccine R&D, and gene editing applications

cyagen.com
4Custom Cell Line Services
TypeProfessional Services
Description

iPSC services, knockout/knockin cell lines, point mutation cell lines, and overexpression cell lines for genetic studies, drug screening, and therapeutic development

cyagen.com
5Antibody Discovery Services
TypeProfessional Services
Description

Fully human antibody discovery using proprietary HUGO-Ab™ platforms combined with AI-powered AbSeek™ screening for therapeutic antibody development

cyagen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1YIMA Gene
Description

High-throughput AAV vector discovery platform subsidiary under Cyagen Group, focused on AI-driven gene therapy research and development.

cyagen.com
+5 more records
Core offering1 text field

Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) that generates genetically engineered mouse and rat models (knockout, knockin, transgenic, humanized) and provides preclinical research services for biopharmaceutical and academic customers. Core offerings include the HUGO series of humanized mouse platforms (HUGO-GT for gene therapy, HUGO-Ab family for antibody discovery), the MouseAtlas catalog of 18,000+ validated strains, custom cell line development, virus packaging (AAV, lentivirus, adenovirus), AI-powered antibody discovery via the AbSeek platform, and preclinical efficacy studies spanning oncology, neuroscience, metabolic, ophthalmology, and autoimmune disease areas.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) providing an integrated platform of genetically engineered animal models, cell models, and preclinical research services. The core offerings include the HUGO Series humanized mouse platforms (HUGO-GT™ for gene therapy, HUGO-Ab™ family for antibody discovery including HUGO-Mab™, HUGO-Light™, HUGO-Ab-eKO™, and HUGO-Nano™), the MouseAtlas Model Library catalog of 18,000+ validated strains, and comprehensive CRO services spanning preclinical efficacy studies, virus packaging, and AI-powered discovery through the AbSeek™ computational platform. The platform supports research across oncology, metabolic diseases, autoimmunity, neuroscience, and ophthalmology with end-to-end capabilities from model generation through IND-enabling studies.

Product and service17 records
1HUGO-GT™ (Humanized Genomic Ortholog)
CategoryHumanized Mouse Models
Description

Genome-wide humanized mouse platform enabling full-length human gene replacement for evaluating gene-editing therapies including antisense oligonucleotides (ASOs) and siRNAs with high translational efficiency.

2HUGO-Ab™ Fully Human Antibody Mouse Platform
CategoryAntibody Discovery Platform
Description

Integrated fully human antibody mouse platform encompassing HUGO-Mab™, HUGO-Light™, and HUGO-Nano™ for generating high-affinity human monoclonal, bispecific, and nanobody antibody candidates.

3HUGO-Mab™ Fully Human Monoclonal Antibody Mouse
CategoryAntibody Discovery Platform
Description

Fully human monoclonal antibody mouse platform for efficient generation of high-affinity human antibody candidates for therapeutic antibody discovery.

4HUGO-Light™ Fully Human Common Light Chain Mouse
CategoryAntibody Discovery Platform
Description

Fully human common light chain antibody mouse designed for bispecific antibody discovery, addressing heavy-light chain mispairing challenges.

5HUGO-Nano™ Fully Human Nanobody Mouse
CategoryAntibody Discovery Platform
Description

Fully human nanobody mouse platform generating heavy-chain-only antibodies (HCAbs) that can be engineered into next-generation bispecific antibodies for enhanced T-cell-mediated anti-tumor responses.

6HUGO-Ab-eKO™ Target Knockout Antibody Discovery
CategoryAntibody Discovery Platform
Description

Target knockout antibody discovery platform enabling enhanced antibody development through genetic modification of target genes.

7MouseAtlas Model Library
CategoryResearch Model Catalog
Description

Comprehensive catalog of over 18,000 validated mouse strains including knockout, knockin, conditional, and humanized models spanning multiple research areas, available for purchase and delivery.

8Genetically Engineered Animals (Custom Model Generation)
CategoryCustom Model Generation Service
Description

Custom generation of knockout, knockin, and transgenic mouse and rat models with high genetic precision for research in genetics, pharmacology, and disease modeling.

9Virus Packaging Services
CategoryVirus Packaging Service
Description

AAV, lentivirus, and adenovirus packaging services for gene therapy, vaccine R&D, and gene editing applications.

10AI-Powered AAV Discovery
CategoryGene Therapy Discovery Service
Description

AI-enabled adeno-associated virus (AAV) vector discovery platform for identifying novel AAV capsids with enhanced tissue targeting capability, tissue specificity, and productivity.

11AbSeek™ Intelligent Computing Platform
CategoryAI Antibody Discovery Service
Description

AI-driven antibody computational platform integrating molecular dynamics simulations, generative AI models, and immunogenicity prediction algorithms for sequence generation, structural prediction, and developability optimization.

12Preclinical Efficacy CRO Services
CategoryPreclinical CRO Service
Description

Comprehensive CRO services covering neuroscience, oncology, metabolic diseases, autoimmunity, and ophthalmology with in vivo study execution capabilities for therapeutic development.

13Custom Cell Line Services
CategoryCustom Cell Line Service
Description

Custom induced pluripotent stem cell (iPSC), knockout, knockin, point mutation, and overexpression cell line services for genetic studies, drug screening, and therapeutic development.

14Humanized Immune System Mouse Models
CategoryHumanized Research Models
Description

PBMC and HSC humanized mouse models for immuno-oncology research and human immune system studies.

15Metabolic Disease Mouse Models
CategoryDisease-Specific Research Models
Description

Disease-specific mouse models including obesity, diabetes, and cardiovascular models such as B6-hINHBE, B6-hALK7, and B6-hPCSK9.

16Oncology & Immuno-oncology Mouse Models
CategoryDisease-Specific Research Models
Description

Tumor and immuno-oncology mouse models for cancer research and therapeutic evaluation.

17hCRBN Humanized Mouse Models
CategoryHumanized Research Models
Description

Humanized CRBN mouse models (Product No. C001683 and C001724) for preclinical evaluation of CRBN-recruiting PROTAC degraders and molecular glues.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Macau University of Science and Technology (M.U.S.T.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Five-year strategic partnership announced June 8, 2026, combining M.U.S.T.'s translational medicine expertise with Cyagen's AI-computational tools and fully human mouse models to advance next-generation fully human antibody discovery. The alliance aims to break through traditional bottlenecks in therapeutic antibody discovery and accelerate IND-enabling timelines through integration of AI, antibody engineering, bioinformatics, and translational drug development. Partners will jointly develop an international innovation platform for AI-driven therapeutic antibody discovery, establish advanced antibody research systems, and accelerate translation of novel antibody candidates into global development programs.

cyagen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-04
Description

Collaboration to streamline access to preclinical mouse and rat models. Taconic and Cyagen partner to provide customers expanded access to validated preclinical models through combined model libraries and services.

Strategic tierSecondaryTypeGTM or Marketing PartnerAnnounced on2025-06-12
Description

Strategic co-marketing agreement between YIMA Gene (subsidiary under Cyagen Group) and ZIP Solutions (Barcelona, 100% affiliate of Biat Group) for gene therapy. YIMA provides AI-driven high-throughput AAV vector discovery platform while ZIP Solutions contributes innovative 'Click-Gene' tool based on proprietary split-inteins for enhanced tissue targeting and expanded genetic cargo capacity. The partnership includes joint marketing initiatives, collaborative research projects, and joint customer support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Strategic collaboration between YIMA Gene and Neurophth Therapeutics to jointly develop next-generation AAV gene therapy vectors targeting specific types of genetic ophthalmic disorders. YIMA could receive milestone payments during research and clinical phases, plus sales royalties potentially surpassing $140 million.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-23
Description

Strategic co-marketing partnership announced at AALAS 2023 combining HistoWiz's automated histology and digitized pathology solutions with Cyagen's custom animal model capabilities. Provides researchers end-to-end capabilities from CAM development through tissue analysis and data digitization. Initial focus on ophthalmology, neurology, and immuno-oncology research. Both companies gain access to each other's products and services including routine tissue processing, advanced immunostaining (IHC, IF, ISH), image analysis, and pathologist consultation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ozgene is an Australian transgenic and knockout rodent CRO, offering directly comparable custom model generation and Cre/lox services to Cyagen's research model business.

TypeDirect peer
Description

Crown Bioscience (JSR Life Sciences) provides preclinical CRO services with strong oncology and immuno-oncology focus, competing directly with Cyagen's oncology efficacy and humanized immune system mouse offerings.

TypeDirect peer
Description

GemPharmatech is a Chinese preclinical CRO offering large-scale humanized and immunodeficient mouse models, directly competing with Cyagen's research model catalog and serving overlapping biopharma and academic customers.

TypeDirect peer
Description

Biocytogen operates RenMab/RenNano humanized mouse platforms and integrated antibody discovery services, directly competing with Cyagen's HUGO-Ab™ family and AbSeek™ AI platform for therapeutic antibody discovery customers.

TypeDirect peer
Description

Genoway is a European specialist in custom genetically engineered mouse and rat models, directly competing with Cyagen's Turboknockout™ and custom model generation services for academic and biotech customers.

TypeBroad incumbent
Description

JAX is the largest nonprofit provider of genetically defined mouse models with deep academic and pharma penetration, competing with Cyagen in the research model catalog space and serving as the gold-standard reference for many institutions.

TypeDirect peer
Description

Taconic is a leading commercial provider of genetically engineered rodent models and also a Cyagen distribution partner, making it both a competitor in model provision and a route-to-market for Cyagen products.

TypeBroad incumbent
Description

Charles River is the largest preclinical CRO globally, offering end-to-end discovery and safety assessment services that compete with Cyagen's preclinical efficacy offerings while also providing alternative sourcing for genetically engineered models.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO with extensive preclinical capabilities including custom model generation, overlapping with Cyagen across research models, cell lines, and preclinical efficacy services.

TypeDirect peer
Description

Ingenious Targeting Laboratory is a US-based gene targeting CRO specializing in custom knockout, knockin, and conditional mouse models, directly competing with Cyagen for academic and biotech model generation contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyagen Biosciences

Preclinical CRO Servicescyagen.com

Cyagen Biosciences is a private AI-enabled preclinical CRO that designs genetically engineered rodent models, humanized mouse platforms, and antibody discovery services for biopharmaceutical companies, academic researchers, and antibody therapeutics developers worldwide.

What Cyagen Biosciences does

Cyagen Biosciences is a privately held, AI-enabled preclinical contract research organization founded in 2006 and headquartered in Santa Clara, California, with principal research and operational facilities in Taicang, Jiangsu, China. The company specializes in the design, generation, and commercialization of genetically engineered rodent models (primarily knockout, knockin, transgenic, and humanized mice and rats), custom cell line services, virus packaging, and integrated preclinical efficacy studies across oncology, neuroscience, metabolic and cardiovascular disease, ophthalmology, and autoimmune and inflammatory disease. Its proprietary platform portfolio centers on the HUGO™ family of humanized mouse systems—HUGO-GT™ for gene therapy and oligonucleotide target validation, and the HUGO-Ab™ sub-family (HUGO-Mab™, HUGO-Light™, HUGO-Nano™, HUGO-Ab-eKO™) for fully human antibody and bispecific discovery—combined with the Turboknockout™ gene targeting technology, Cre-ESCs editing, and the Cell iGeneEditor™ / AlphaKnockout systems. More than 50,000 mouse and rat models have been delivered globally, with 16,500+ peer-reviewed SCI citations referencing Cyagen models and services, 250,000 SPF animals housed in AAALAC-accredited facilities, and a workforce exceeding 1,000 employees across 40,000+ square meters of operational footprint.

Cyagen Biosciences firmographics

Firmographics
Name
Cyagen Biosciences
Legal name
Cyagen Biomodels LLC
Website
https://cyagen.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Cyagen Biosciences is a private AI-enabled preclinical CRO that designs genetically engineered rodent models, humanized mouse platforms, and antibody discovery services for biopharmaceutical companies, academic researchers, and antibody therapeutics developers worldwide.
Ownership category
akta.pro rank

Cyagen Biosciences industry classification

Industry
Product category
Preclinical CRO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Genetically engineered models
  • Preclinical CRO services
  • Humanized mouse models
  • Antibody discovery services
  • Virus packaging services

Where Cyagen Biosciences is headquartered

Location

Headquarters

HQ city
Santa Clara
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cyagen Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Custom Genetically Engineered Animal Models: Generation of knockout, knockin, transgenic, and humanized mouse and rat models for preclinical research. Revenue generated through one-time model generation projects and repeat breeding services.
  2. Preclinical CRO Services: Comprehensive preclinical efficacy studies including neuroscience, oncology, ophthalmology, metabolic diseases, autoimmunity, and inflammation research services. Services include breeding, cryopreservation, phenotyping, and custom study execution.
  3. Virus Packaging Services: AAV, lentivirus, and adenovirus packaging for gene therapy, vaccine R&D, and gene editing applications
  4. Custom Cell Line Services: iPSC services, knockout/knockin cell lines, point mutation cell lines, and overexpression cell lines for genetic studies, drug screening, and therapeutic development
  5. Antibody Discovery Services: Fully human antibody discovery using proprietary HUGO-Ab™ platforms combined with AI-powered AbSeek™ screening for therapeutic antibody development

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Cyagen Biosciences product offering

Product offering

Core offering

Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) that generates genetically engineered mouse and rat models (knockout, knockin, transgenic, humanized) and provides preclinical research services for biopharmaceutical and academic customers. Core offerings include the HUGO series of humanized mouse platforms (HUGO-GT for gene therapy, HUGO-Ab family for antibody discovery), the MouseAtlas catalog of 18,000+ validated strains, custom cell line development, virus packaging (AAV, lentivirus, adenovirus), AI-powered antibody discovery via the AbSeek platform, and preclinical efficacy studies spanning oncology, neuroscience, metabolic, ophthalmology, and autoimmune disease areas.

Product overview

Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) providing an integrated platform of genetically engineered animal models, cell models, and preclinical research services. The core offerings include the HUGO Series humanized mouse platforms (HUGO-GT™ for gene therapy, HUGO-Ab™ family for antibody discovery including HUGO-Mab™, HUGO-Light™, HUGO-Ab-eKO™, and HUGO-Nano™), the MouseAtlas Model Library catalog of 18,000+ validated strains, and comprehensive CRO services spanning preclinical efficacy studies, virus packaging, and AI-powered discovery through the AbSeek™ computational platform. The platform supports research across oncology, metabolic diseases, autoimmunity, neuroscience, and ophthalmology with end-to-end capabilities from model generation through IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Brands

  • YIMA Gene: High-throughput AAV vector discovery platform subsidiary under Cyagen Group, focused on AI-driven gene therapy research and development.
  • HUGO-GT™
  • HUGO-Ab™
  • AbSeek™
  • HUGO-GT™
  • Cyagen

Products and services

  • HUGO-GT™ (Humanized Genomic Ortholog) Genome-wide humanized mouse platform enabling full-length human gene replacement for evaluating gene-editing therapies including antisense oligonucleotides (ASOs) and siRNAs with high translational efficiency.
  • HUGO-Ab™ Fully Human Antibody Mouse Platform Integrated fully human antibody mouse platform encompassing HUGO-Mab™, HUGO-Light™, and HUGO-Nano™ for generating high-affinity human monoclonal, bispecific, and nanobody antibody candidates.
  • HUGO-Mab™ Fully Human Monoclonal Antibody Mouse Fully human monoclonal antibody mouse platform for efficient generation of high-affinity human antibody candidates for therapeutic antibody discovery.
  • HUGO-Light™ Fully Human Common Light Chain Mouse Fully human common light chain antibody mouse designed for bispecific antibody discovery, addressing heavy-light chain mispairing challenges.
  • HUGO-Nano™ Fully Human Nanobody Mouse Fully human nanobody mouse platform generating heavy-chain-only antibodies (HCAbs) that can be engineered into next-generation bispecific antibodies for enhanced T-cell-mediated anti-tumor responses.
  • HUGO-Ab-eKO™ Target Knockout Antibody Discovery Target knockout antibody discovery platform enabling enhanced antibody development through genetic modification of target genes.
  • MouseAtlas Model Library Comprehensive catalog of over 18,000 validated mouse strains including knockout, knockin, conditional, and humanized models spanning multiple research areas, available for purchase and delivery.
  • Genetically Engineered Animals (Custom Model Generation) Custom generation of knockout, knockin, and transgenic mouse and rat models with high genetic precision for research in genetics, pharmacology, and disease modeling.
  • Virus Packaging Services AAV, lentivirus, and adenovirus packaging services for gene therapy, vaccine R&D, and gene editing applications.
  • AI-Powered AAV Discovery AI-enabled adeno-associated virus (AAV) vector discovery platform for identifying novel AAV capsids with enhanced tissue targeting capability, tissue specificity, and productivity.
  • AbSeek™ Intelligent Computing Platform AI-driven antibody computational platform integrating molecular dynamics simulations, generative AI models, and immunogenicity prediction algorithms for sequence generation, structural prediction, and developability optimization.
  • Preclinical Efficacy CRO Services Comprehensive CRO services covering neuroscience, oncology, metabolic diseases, autoimmunity, and ophthalmology with in vivo study execution capabilities for therapeutic development.
  • Custom Cell Line Services Custom induced pluripotent stem cell (iPSC), knockout, knockin, point mutation, and overexpression cell line services for genetic studies, drug screening, and therapeutic development.
  • Humanized Immune System Mouse Models PBMC and HSC humanized mouse models for immuno-oncology research and human immune system studies.
  • Metabolic Disease Mouse Models Disease-specific mouse models including obesity, diabetes, and cardiovascular models such as B6-hINHBE, B6-hALK7, and B6-hPCSK9.
  • Oncology & Immuno-oncology Mouse Models Tumor and immuno-oncology mouse models for cancer research and therapeutic evaluation.
  • hCRBN Humanized Mouse Models Humanized CRBN mouse models (Product No. C001683 and C001724) for preclinical evaluation of CRBN-recruiting PROTAC degraders and molecular glues.

Companies that use Cyagen Biosciences

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Cyagen Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Cyagen Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and secondary.

  • Macau University of Science and Technology (M.U.S.T.)coreStrategic or Co-development Partner · 8 June 2026Five-year strategic partnership announced June 8, 2026, combining M.U.S.T.'s translational medicine expertise with Cyagen's AI-computational tools and fully human mouse models to advance next-generation fully human antibody discovery. The alliance aims to break through traditional bottlenecks in therapeutic antibody discovery and accelerate IND-enabling timelines through integration of AI, antibody engineering, bioinformatics, and translational drug development. Partners will jointly develop an international innovation platform for AI-driven therapeutic antibody discovery, establish advanced antibody research systems, and accelerate translation of novel antibody candidates into global development programs.
  • TaconiccoreChannel Partner/ Reseller/ Distributor · 4 August 2025Collaboration to streamline access to preclinical mouse and rat models. Taconic and Cyagen partner to provide customers expanded access to validated preclinical models through combined model libraries and services.
  • ZIP SolutionssecondaryGTM or Marketing Partner · 12 June 2025Strategic co-marketing agreement between YIMA Gene (subsidiary under Cyagen Group) and ZIP Solutions (Barcelona, 100% affiliate of Biat Group) for gene therapy. YIMA provides AI-driven high-throughput AAV vector discovery platform while ZIP Solutions contributes innovative 'Click-Gene' tool based on proprietary split-inteins for enhanced tissue targeting and expanded genetic cargo capacity. The partnership includes joint marketing initiatives, collaborative research projects, and joint customer support.
  • Neurophth Therapeutics, Inc.coreStrategic or Co-development Partner · 1 November 2024Strategic collaboration between YIMA Gene and Neurophth Therapeutics to jointly develop next-generation AAV gene therapy vectors targeting specific types of genetic ophthalmic disorders. YIMA could receive milestone payments during research and clinical phases, plus sales royalties potentially surpassing $140 million.
  • HistoWizcoreStrategic or Co-development Partner · 23 October 2023Strategic co-marketing partnership announced at AALAS 2023 combining HistoWiz's automated histology and digitized pathology solutions with Cyagen's custom animal model capabilities. Provides researchers end-to-end capabilities from CAM development through tissue analysis and data digitization. Initial focus on ophthalmology, neurology, and immuno-oncology research. Both companies gain access to each other's products and services including routine tissue processing, advanced immunostaining (IHC, IF, ISH), image analysis, and pathologist consultation.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Cyagen Biosciences competitors and assessment

Company assessment

Direct peers

  • Ozgene: Ozgene is an Australian transgenic and knockout rodent CRO, offering directly comparable custom model generation and Cre/lox services to Cyagen's research model business.
  • Crown Bioscience: Crown Bioscience (JSR Life Sciences) provides preclinical CRO services with strong oncology and immuno-oncology focus, competing directly with Cyagen's oncology efficacy and humanized immune system mouse offerings.
  • GemPharmatech: GemPharmatech is a Chinese preclinical CRO offering large-scale humanized and immunodeficient mouse models, directly competing with Cyagen's research model catalog and serving overlapping biopharma and academic customers.
  • Biocytogen: Biocytogen operates RenMab/RenNano humanized mouse platforms and integrated antibody discovery services, directly competing with Cyagen's HUGO-Ab™ family and AbSeek™ AI platform for therapeutic antibody discovery customers.
  • Genoway: Genoway is a European specialist in custom genetically engineered mouse and rat models, directly competing with Cyagen's Turboknockout™ and custom model generation services for academic and biotech customers.
  • Taconic Biosciences: Taconic is a leading commercial provider of genetically engineered rodent models and also a Cyagen distribution partner, making it both a competitor in model provision and a route-to-market for Cyagen products.
  • Ingenious Targeting Laboratory: Ingenious Targeting Laboratory is a US-based gene targeting CRO specializing in custom knockout, knockin, and conditional mouse models, directly competing with Cyagen for academic and biotech model generation contracts.

Broad incumbents

  • The Jackson Laboratory: JAX is the largest nonprofit provider of genetically defined mouse models with deep academic and pharma penetration, competing with Cyagen in the research model catalog space and serving as the gold-standard reference for many institutions.
  • Charles River Laboratories: Charles River is the largest preclinical CRO globally, offering end-to-end discovery and safety assessment services that compete with Cyagen's preclinical efficacy offerings while also providing alternative sourcing for genetically engineered models.
  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO with extensive preclinical capabilities including custom model generation, overlapping with Cyagen across research models, cell lines, and preclinical efficacy services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cyagen Biosciences social profiles

Digital presence

Cyagen Biosciences compliance and trust

Trust signal

Compliance1 record

Cyagen Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyagen Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Cyagen Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Cyagen Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyagen Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyagen Biosciences

What does Cyagen Biosciences do?

Cyagen Biosciences is an AI-enabled Contract Research Organization (CRO) that generates genetically engineered mouse and rat models (knockout, knockin, transgenic, humanized) and provides preclinical research services for biopharmaceutical and academic customers. Core offerings include the HUGO series of humanized mouse platforms (HUGO-GT for gene therapy, HUGO-Ab family for antibody discovery), the MouseAtlas catalog of 18,000+ validated strains, custom cell line development, virus packaging (AAV, lentivirus, adenovirus), AI-powered antibody discovery via the AbSeek platform, and preclinical efficacy studies spanning oncology, neuroscience, metabolic, ophthalmology, and autoimmune disease areas.

Is Cyagen Biosciences a public or private company?

Cyagen Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cyagen Biosciences founded?

Cyagen Biosciences was founded in 2006. It employs 101 to 250 people.

Where is Cyagen Biosciences based?

Cyagen Biosciences is headquartered in Santa Clara, United States, in the North America region.

How does Cyagen Biosciences make money?

Five revenue lines are on record. Custom Genetically Engineered Animal Models are the primary driver. The others are preclinical CRO Services, virus Packaging Services, custom Cell Line Services and antibody Discovery Services.

Who are Cyagen Biosciences's main competitors?

Direct peers on record are Ozgene, Crown Bioscience, GemPharmatech, Biocytogen, Genoway, Taconic Biosciences and Ingenious Targeting Laboratory. Broad incumbents are The Jackson Laboratory, Charles River Laboratories and WuXi AppTec.

Does Cyagen Biosciences have an API?

No public API is recorded for Cyagen Biosciences.

What industry is Cyagen Biosciences in?

Cyagen Biosciences's product category is Preclinical CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Global Market Insights Inc.Mesenchymal Stem Cells Market StatisticsThe mesenchymal stem cells market was valued at USD 3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 12.8% to reach approximately USD 10.3 billion by 2032, driven by the increasing prevalence of chronic diseases and applications in regenerative medicine. Key players involved in this market include Thermo Fisher Scientific, Cell Applications, and Cyagen Biosciences, among others. The pandemic has also highlighted the therapeutic potential of mesenchymal stem cells in treating COVID-19 complications, leading to increased investment in research and development in this area.36krPharmaceutical CXOs Stocks Surge Sharply Across the Board: Real Industry Recovery or Hype-Driven Rally?The CXO industry shows structural differences: some firms are releasing profits rapidly, others are ramping up orders, and some are stuck in transformation pains. No specific figures or forward-looking details are provided.openPR.comKaryotyping Service Market to Witness Impressive Growth by 2030: Igeno mix, Lab corp, CyagenHTF Market Intelligence released a study forecasting the global Karyotyping Service market to grow impressively through 2030, driven by increasing maternal age and the adoption of prenatal testing for genetic disorders. The report identifies key industry players including Thermo Fisher, Lab corp, and Cyagen, while noting trends such as the shift toward non-invasive prenatal testing and rapid diagnostic techniques. It provides segmented data on market size, revenue, and growth rates across major geographic regions including North America, Europe, and Asia-Pacific.PLOSCorrection: USP12 promotes antiviral responses by deubiquitinating and stabilizing IFI16A correction was issued for a previously published scientific article regarding gene nomenclature errors, specifically clarifying that the mouse ortholog p204 (Ifi204) was mistakenly referred to as human IFI16. The corresponding author provided updated figures, data files, and clarified the origins of the mouse models generated by Cyagen Biosciences Inc. and the Shanghai Research Center for Model Organisms.The Japan TimesGenetically modified mice at $17,000 a pair in high demand as China bids to be biomedical powerhouse - The Japan TimesCyagen Biosciences Inc. is capitalizing on soaring demand for genetically modified laboratory mice in China, where pairs sell for up to $17,000 as the country pursues its goal of becoming a biomedical powerhouse by 2025. The company has expanded operations with new facilities in Guangzhou and Shanghai to supply universities and pharmaceutical companies, contributing to a global market for gene-altered mice projected to reach $1.59 billion by 2022.BloombergChina's Demand for $17,000 Gene-Altered Lab Mice Is Skyrocketing - BloombergDemand for genetically altered laboratory mice in China is surging, with Cyagen Biosciences Inc. selling pairs for up to $17,000. This high-value market reflects the growing commercialization of gene-editing technologies within the country's biotech sector.openPR.comTransgenic Animals Market - An overview | Key players | Production and Application - Industry Insight 2018-2023The transgenic animals market is expected to grow at a compound annual growth rate (CAGR) of 8.60% from 2017 to 2023, driven by advancements in biotechnology and increasing healthcare expenditures. Key players in the market include Cyagen Biosciences and Thermo Fisher Scientific Inc., among others, with applications ranging from producing human proteins to medical research. However, stringent FDA policies and high production costs are significant challenges facing the market.GlobeNewswireTaconic Biosciences and Cyagen Biosciences Announce Strategic PartnershipTaconic Biosciences and Cyagen Biosciences announced a strategic partnership to combine resources for custom genetically engineered rodent model services. The alliance aims to offer customers expanded expertise, pricing flexibility, and faster timelines through a single point of contact. The companies will integrate over twenty years of combined experience and technology portfolios.